UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020402
Receipt number R000023563
Scientific Title Improvement of treatment in ulcerative colitis, severe case and moderate case close to severe case, by early use of infliximab
Date of disclosure of the study information 2015/12/30
Last modified on 2020/08/12 05:10:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Improvement of treatment in ulcerative colitis, severe case and moderate case close to severe case, by early use of infliximab

Acronym

Early use of infliximab in severe case and moderate case close to severe case of ulcerative colitis

Scientific Title

Improvement of treatment in ulcerative colitis, severe case and moderate case close to severe case, by early use of infliximab

Scientific Title:Acronym

Early use of infliximab in severe case and moderate case close to severe case of ulcerative colitis

Region

Japan


Condition

Condition

ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Improvement of treatment in ulcerative colitis, severe case and moderate case close to severe case, by early use of infliximab

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Remission rate at 6 weeks after the initiation of treatment

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

10 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

Ulceraive colitis, severe case or moderate case close to severe case, who is naive to biologics

Key exclusion criteria

mild case, moderate case close to mild case

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Mitsuro
Middle name
Last name Chiba

Organization

Akita City Hospital

Division name

Gastroenterology

Zip code

010-0933

Address

Akita

TEL

0188234171

Email

mchiba@m2.gyao.ne.jp


Public contact

Name of contact person

1st name Takenori
Middle name
Last name Kawakami

Organization

Akita city Hospital

Division name

General Administration Division

Zip code

010-0933

Address

Akita

TEL

0188234171

Homepage URL


Email

mchiba@m2.gyao.ne.jp


Sponsor or person

Institute

IBD Relapse Prevention Team

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethical Committee of Akita City Hospital

Address

4-30, Matsuoka-machi, Kawamoto, Akita City

Tel

0188234171

Email

ro-homn@city.akita.akita.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2010 Year 07 Month 01 Day

Date of IRB

2014 Year 03 Month 28 Day

Anticipated trial start date

2010 Year 07 Month 01 Day

Last follow-up date

2019 Year 09 Month 15 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Assessment at week 6 since the commencement of a standard induction therapy with infliximab
Clinical remission: disappearance of symptoms including bloody stool
Mucosal healing: disappearance of ulcers and erosions


Management information

Registered date

2015 Year 12 Month 30 Day

Last modified on

2020 Year 08 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023563


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name